25 companies to make a career in Italy; Finalist for the European Inventor Award 2021 #2

We weekly offer stories, market data, insights, and hand-picked resources to better grasp the dynamics of the Italian business landscape, get inspired, and activated.

The 25 companies to make a career in Italy according to Linkedin

Which companies today in Italy offer the most career opportunities? Linkedin has compiled the Top Companies 2021, which includes the 25 companies considered by Italians as the workplaces that offer the greatest prospects for growth. In 50% of cases, they are companies of Italian origin or with Italian participation.

  1. Intesa Sanpaolo, 77,000 employees in Italy;

  2. Accenture, 17,000 employees in Italy;

  3. Stellantis, 55,000 employees in Italy;

  4. Generali Assicurazioni, 13,000 employees in Italy;

  5. Unicredit, 35,800 employees in Italy;

  6. Comcast+Sky Italia, 5,350 employees in Italy;

  7. Deloitte, 8,300 employees in Italy;

  8. STMicroelectronics, 10,700 employees in Italy;

  9. BNP Paribas, 18,000 employees in Italy;

  10. ENI, 21,000 employees in Italy;

  11. Leonardo, 31,000 employees in Italy;

  12. GSK, 4,300 employees in Italy;

  13. Capgemini, 4,330 employees in Italy;

  14. PwC, 6,400 employees in Italy;

  15. Abb, 5,880 employees in Italy;

  16. Reply, 5,600 employees in Italy;

  17. Enel, 29,000 employees in Italy;

  18. TIM, 42,680 employees in Italy;

  19. Volkswagen, 5,900 employees in Italy;

  20. Deutsche Bank;

  21. Banca Mediolanum;

  22. Axa Assicurazioni;

  23. EssilorLuxottica;

  24. Siemens, 3,000 employees in Italy;

  25. Johnson & Johnson, 2,870 employees in Italy.

Finalist for the European Inventor Award 2021

Italian physicist Marco Donolato is one of the 2021 European Inventor Award finalists.

Marco Donolato and his team invented a test capable of identifying some infectious diseases, including dengue fever - which is estimated to infect 390 million people each year. The new test requires a single drop of blood to give rapid and accurate results and therefore allows a prompt treatment of patients.

In many countries, many people cannot receive the diagnosis and treatment of infectious diseases due to the inaccessibility of neighboring laboratories or for excessive cost.

Dengue fever is a viral infection that affects nearly 400 million people each year, but early diagnosis and access to medical care could reduce its mortality from 20% to less than 1%. However, an additional problem is that conventional tests take many hours and specialized personnel.

Marco Donolato first came up with the idea of using magnetic nanoparticles (MNPs) to diagnose diseases, when working in the laboratory of Professor Mikkel Fougt Hansen, a doctor specializing in MNPs research, at the Technical University in Denmark.

Later he also worked for some time with Professor Paolo Vavassori - engineer specializing in optoelectronics, at the CIC nanoGUNE in Spain.

Building on the twofold experience, Donolato and his team were able to develop a test using MNPs and an optical device of the type used in common Blu-ray players.

The invention includes a ViroTrack cartridge containing MNP coated with disease-related antibodies for which the patient is being tested. This cartridge is inserted into a BluBox optical reader, which uses blue laser technology and an oscillating magnetic field to determine whether the disease is present from configurations created by MNPs.

The patented system is able to identify the virus and quantify it from a drop of blood, taken from the patient's fingertip, in about 10 minutes.

The test is automatic, economical, and easy to perform even by unskilled personnel: this makes it ideal for use in rural areas of developing countries.

Donolato's invention was marketed through BluSense Diagnostics, the start-up he founded together with Hansen and Vavassori in 2014. Today the company has more than 60 employees and has been financed with over 15 million euros.

Other tests are under development for zika virus, chikungunya, yellow fever, and West Nile fever.

In response to the current pandemic, the company is working on a new product to measure a patient's antibody response to COVID-19 in just 5 minutes.

Share Italy in Perspective